Evidence map›Paper›PMID 40395807›Full record

ArticleFrontiers in veterinary science2025

The alleviating effects and mechanisms of

Rui Zhang, Wanjin Hu, Saiwei Zhong, Weiyang Chen, Shuang Xie, Meiru Chen, Qinghua Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Synthetic and systems biotechnology · 2027
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rui Zhang *College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China.
Wanjin Hu *Laboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China.
Saiwei Zhong *Laboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China.
Weiyang ChenLaboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China.
Shuang XieCollege of Animal Science and Technology of Jiangxi Agricultural University, Nanchang, China.
Meiru ChenLaboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China.
Qinghua YuLaboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co., Limited, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Canine inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and dysbiosis. Conventional treatments often result in adverse effects and contribute to antibiotic resistance, highlighting the need for safe, effective alternatives. Probiotics have gained attention for their potential in modulating gut microbiota and immune responses. This study investigates the therapeutic mechanisms of Methods: Results: Kimate-F showed strong antibacterial effects against Discussion: These findings suggest that

Indexed as

canine inflammatory bowel diseasedysbiosisEnterococcus faeciuminflammationLactobacillus plantarumprobiotics

Identifiers

PMID40395807
PMCPMC12090933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.